https://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Tue, 16 Oct 2018 14:49:37 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - SkinBioTherapeutics first-in-human trial of cream underway ]]> https://www.proactiveinvestors.co.uk/companies/news/205197/skinbiotherapeutics-first-in-human-trial-of-cream-underway-205197.html SkinBioTherapeutics PLC (LON:SBTX) said first-in-human studies of its SkinBiotix technology are underway.

Researchers will be assessing skin irritancy, moisturisation potential and skin barrier function.

Results from the initial trial, which will test different concentrations of the cream, are due next months as is the read-out from the second, which will assess 20 people receiving a 12-hour treatment.

The skin barrier study is the most ambitious of the three. It will attempt to ascertain whether the positive impact of the technology on the skin's barrier function seen in the lab is replicated in 120 female volunteers with dry skin.

Tight junctions

Work in this regard will get underway in November with the data published in the first quarter of next year.

The cream uses extracts of probiotic bacteria that have been shown to increase the skin's barrier integrity by enhancing the formation of multi-protein complexes called tight junctions.

Tight junctions seal the space between cells to prevent the passage of toxins, molecules and ions through these spaces.

In doing so, it is hoped the cream can protect the body’s largest organ from harmful pathogens and increase its rate of healing.

]]>
Wed, 19 Sep 2018 08:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205197/skinbiotherapeutics-first-in-human-trial-of-cream-underway-205197.html
<![CDATA[RNS press release - Human study commenced ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180919070002_13795773/ Wed, 19 Sep 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180919070002_13795773/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180918140558_13795259/ Tue, 18 Sep 2018 14:05:58 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180918140558_13795259/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180918140033_13795249/ Tue, 18 Sep 2018 14:00:33 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180918140033_13795249/ <![CDATA[News - SkinBioTherapeutics cream successful in stability testing ]]> https://www.proactiveinvestors.co.uk/companies/news/204031/skinbiotherapeutics-cream-successful-in-stability-testing-204031.html SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology was successful in stability-testing.

"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month," said chief executive, Dr Cath O’Neill.

WATCH: SkinBioTherapeutics achieves 'commercial levels of scale-up' of its technology

The cream uses extracts of probiotic bacteria that have been shown to increase the skin's barrier integrity by enhancing the formation of multi-protein complexes called tight junctions.

Tight junctions seal the space between cells to prevent the passage of toxins, molecules and ions through these spaces.

Human studies

In doing so, it is hoped the cream can protect the body’s largest organ from harmful pathogens and increase its rate of healing.

The company’s first-in-human study of SkinBiotix will be carried out over 30 days to assess skin hydration and barrier function. 

In parallel, the formulations will also be assessed to ensure that no inflammation of the skin occurs.

If positive, the data will allow the company to use the term 'dermatologically tested' for its formulations.

The shares rose 15% to 22.34p, valuing the business at £26mln. In the past six months, the stock has more than doubled in value.

]]>
Mon, 03 Sep 2018 07:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204031/skinbiotherapeutics-cream-successful-in-stability-testing-204031.html
<![CDATA[RNS press release - SkinBiotix technology successful in stability test ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180903070006_13775575/ Mon, 03 Sep 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180903070006_13775575/ <![CDATA[Media files - SkinBioTherapeutics achieves 'commercial levels of scale-up' of its technology ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10155/skinbiotherapeutics-achieves-commercial-levels-of-scale-up-of-its-technology-10155.html Thu, 16 Aug 2018 16:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10155/skinbiotherapeutics-achieves-commercial-levels-of-scale-up-of-its-technology-10155.html <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816110532_13758145/ Thu, 16 Aug 2018 11:05:32 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816110532_13758145/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816110014_13758132/ Thu, 16 Aug 2018 11:00:14 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816110014_13758132/ <![CDATA[News - SkinBioTherapeutics successfully scales-up manufacturing ]]> https://www.proactiveinvestors.co.uk/companies/news/203021/skinbiotherapeutics-successfully-scales-up-manufacturing-203021.html Microbiome skincare company SkinBioTherapeutics PLC (LON:SBTX) said it has successfully managed to scale up production with no detrimental impact on the effectiveness of its technology.

The material produced, which to date has been manufactured and supplied in a liquid form, has now been successfully freeze-dried.

SkinBio said the ability to freeze dry the material is an important step towards commercialisation as it enables mass production, storage and transportation.

READ SkinBioTherapeutics receives ethics approval for human trial of SkinBiotix

The company was recently given provisional ethics approval from regulators to commence the human study of its technology and this is scheduled to commence next month, subject to the company being confident of the stability of the current formulation over an extended time-frame.

The company said it would publish its full-year results in October but revealed it ended June with a cash balance of £3.2mln, down from £3.6mln at the end of 2017.

"The progress we've made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study,” said Dr Cath O’Neill, the chief executive officer of SkinBio.

]]>
Thu, 16 Aug 2018 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203021/skinbiotherapeutics-successfully-scales-up-manufacturing-203021.html
<![CDATA[RNS press release - Business Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816070004_13757229/ Thu, 16 Aug 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180816070004_13757229/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180803085703_13742955/ Fri, 03 Aug 2018 08:57:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180803085703_13742955/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180723131313_13727873/ Mon, 23 Jul 2018 13:13:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180723131313_13727873/ <![CDATA[News - SkinBioTherapeutics receives ethics approval for human trial of SkinBiotix ]]> https://www.proactiveinvestors.co.uk/companies/news/201010/skinbiotherapeutics-receives-ethics-approval-for-human-trial-of-skinbiotix-201010.html Life sciences group SkinBioTherapeutics PLC (LON:SBTX) remains on track to kick off the human study of its SkinBiotix technology in September after receiving provisional ethics approval from regulators.

Full approval will be granted on completion of procedural amendments to the study paperwork which are underway.

READ: SBTX to collaborate as industry partner in 'probiotic' skin research grant

“Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence,” said chief executive Catherin O’Neill.

“The procedural amendments we need to make to the paperwork are straightforward and consequently we remain on track to commence the human study in September.”

The study will test whether the positive impact of SkinBiotix on the skin’s barrier function, which has been shown in laboratory studies, is replicated with human volunteers.

Around 120 volunteers with self-assessed ‘dry skin’ will take part in the six-week trial.

]]>
Wed, 18 Jul 2018 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201010/skinbiotherapeutics-receives-ethics-approval-for-human-trial-of-skinbiotix-201010.html
<![CDATA[RNS press release - Provisional ethics approval for human study ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180718070003_13721589/ Wed, 18 Jul 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180718070003_13721589/ <![CDATA[News - SkinBioTherapeutics to collaborate as industry partner in 'probiotic' skin research grant ]]> https://www.proactiveinvestors.co.uk/companies/news/197787/skinbiotherapeutics-to-collaborate-as-industry-partner-in-probiotic-skin-research-grant-197787.html SkinBioTherapeutics PLC (LON:SBTX) said it will fulfil the industrial partner role in a skin health research grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to the University of Manchester.

The AIM-listed skin health company said the £600,000 grant would provide the university with non-dilutive funding for up to three years to investigate how ageing affects the skin and in particular, its microbiome.

READ: SkinBioTherapeutics higher as it files patent application for potential eczema treatment

The firm said that in the human gut, it is currently understood that certain fibres can promote the growth of beneficial bacteria (called a 'prebiotic effect'), but research was needed to determine how this principle could be applied to skin health and which molecules could be prebiotic for the skin's microbiome.

SkinBio added that the grant had been awarded to enable research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health.

The group said, as industrial partner to the research programme, it had first refusal on any intellectual property generated by the project, in addition to being well placed to develop any relevant findings and potentially extend its current portfolio.

Dr Catherine O’Neill, chief executive of SkinBioTherapeutics, said: "We have a long-standing relationship with the University, and I am delighted this will continue through this latest collaboration. It is testament to both teams that we have been successful with such a prestigious award.

She added: "Unlike the gut, virtually nothing is known about possible prebiotics for skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."

In early morning trading Tuesday, SkinBio shares were up 2.9% at 17.5p.

--Adds share price--

]]>
Tue, 29 May 2018 07:17:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197787/skinbiotherapeutics-to-collaborate-as-industry-partner-in-probiotic-skin-research-grant-197787.html
<![CDATA[RNS press release - SkinBioTherapeutics involved in new research grant ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180529070016_13657114/ Tue, 29 May 2018 07:00:16 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180529070016_13657114/ <![CDATA[News - SkinBioTherapeutics higher as it files patent application for potential eczema treatment ]]> https://www.proactiveinvestors.co.uk/companies/news/196878/skinbiotherapeutics-higher-as-it-files-patent-application-for-potential-eczema-treatment-196878.html SkinBioTherapeutics PLC (LON:SBTX) shares rose on Monday on news the firm has filed a patent application for a potential treatment that could help skin conditions such as eczema.

The AIM-listed skin health company said in a statement that the application covered the use of its SkinBiotix technology for increasing filaggrin levels in the skin.

READ: SkinBioTherapeutics finalises plans for cosmetic study; updates on manufacturing scale-up

Filaggrin is a protein that is vital for cells to mature properly into the tough outer layer of the skin, with deficiencies leading to dryness and irritation as well as the potential development of conditions such as eczema.

The company said research in its labs had shown that SkinBiotix could significantly increase the amount of filaggrin in human skin models.

This is the second successful test of the group's technology, following earlier proof that SkinBiotix increases the 'tight junction' which exists in the inner layer of skin.

The company added that the observation that the technology can improve both the surface and inner layers of skin suggests that SkinBiotix would be therapeutically useful in a range of conditions, such as eczema.

SkinBioTherapeutics has already finalised plans for a human study around the cosmetic application of its SkinBiotix technology, which is expected to be carried out in the third quarter of this year.

SkinBiotix continuing to prove its uniqueness

Dr Cath O’Neill, chief executive of SkinBioTherapeutics, said: "SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on filaggrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent.

"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets."

In a note to clients, analysts at 'house' broker Northland Capital commented: “These findings regarding filaggrin production combined with previous observations on tight junctions indicate that the SkinBiotix platform has beneficial properties on both the surface and inner layers of skin and could be therapeutically useful in a range of skin conditions, including eczema.”

They added: “The filing of this patent shows the Company is continuing to protect its IP portfolio surrounding its SkinBiotix technology.

“The Company’s first patent (covering the use of bacteria and lysates in the treatment of skin in health and disease) has been granted in Australia, New Zealand and Russia with active prosecution progressing in Europe, USA and China.”

In early afternoon trading, SkinBioTherapeutics shares were up 6.3% at 17p.

-- Adds analyst comment; updates share price --

]]>
Mon, 14 May 2018 07:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196878/skinbiotherapeutics-higher-as-it-files-patent-application-for-potential-eczema-treatment-196878.html
<![CDATA[RNS press release - SkinBioTherapeutics files new patent application ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180514070011_13639041/ Mon, 14 May 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180514070011_13639041/ <![CDATA[News - SkinBioTherapeutics finalises plans for cosmetic study; updates on manufacturing scale-up ]]> https://www.proactiveinvestors.co.uk/companies/news/196117/skinbiotherapeutics-finalises-plans-for-cosmetic-study-updates-on-manufacturing-scale-up-196117.html SkinBioTherapeutics PLC (LON:SBTX) said it has finalised plans for its human study of the cosmetic application of its SkinBiotix technology while it announced progress with the manufacturing scale-up of the product.

The former first: the assessment of 120 female volunteers with dry skin will take place in the third quarter with testing being carried out by clinical research firm Alba Science.

READ: 'Huge milestone' for SkinBioTherapeutics with cream formulation success

Scientists will assess for visual dryness, skin hydration and skin barrier function with swab samples to be taken at the beginning and end of the study to examine the effects of the technology on the skin microbiome.

By using the cream, it is hoped hydration of the skin will be improved; the barrier function will be stronger (shown by a decrease in water loss across the skin barrier); and it will be confirmed that the technology is safe for the skin microbiome.

Study doubles in size 

"We are determined to make the study as impactful as possible, which is why we have doubled its size,” said chief executive, Dr Cath O'Neill.

“The cost impact is marginal, but the increase in the strength of the potential data and hence, to future partnering discussions, could be significant. Scaling up the manufacturing process is a key step in our development, and we are also moving this forward very well."

Turning to the manufacturing process, SkinBioTherapeutics a new production method that is scalable has been successfully trialled.

The results indicated no detrimental impact upon the active properties of the SkinBiotix technology.

The company said further work is required to optimise the process to achieve manufacturing on a commercial scale but the progress to date is “encouraging”.

In the same announcement, SkinBioTherapeutics said a patent covering the use for specific probiotic bacteria and lysates in skin health has been granted in New Zealand and Russia.

]]>
Tue, 01 May 2018 08:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196117/skinbiotherapeutics-finalises-plans-for-cosmetic-study-updates-on-manufacturing-scale-up-196117.html
<![CDATA[RNS press release - SkinBioTherapeutics plans for human study ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180501070007_13624872/ Tue, 01 May 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180501070007_13624872/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180424085603_13616012/ Tue, 24 Apr 2018 08:56:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180424085603_13616012/ <![CDATA[News - SkinBioTheraputics “significantly undervalued” despite having demonstrated significant progress ]]> https://www.proactiveinvestors.co.uk/companies/news/195382/skinbiotheraputics-significantly-undervalued-despite-having-demonstrated-significant-progress-195382.html Northland Capital believes that SkinBioTheraputics PLC (LON:SBTX) is “significantly undervalued” amongst its peers despite having demonstrated significant progress since its IPO almost exactly a year ago.

In a note to clients initiating coverage on the microbiome skincare company, the joint ‘house’ broker noted that, as SkinBio operates in a new therapeutic area, there is little market data in the sector.

WATCH: 'Huge milestone' for SkinBioTherapeutics with cream formulation success

As a result, Northland said it has compiled a basket of comparable peers operating in the microbiome space, or in the cosmetic goods sector.

The broker noted that, with an average market capitalisation of £73mln for the basket, SkinBio - currently valued at £13.65mln - is significantly below that level.

SkinBio floated on AIM on April 5 last year at 9p a share, which valued the business at around £6mln, after raising £4.5mln from a placing of 50mln new ordinary shares, and the stock has risen by 50% to 12p currently.

Northland noted that SkinBio is an early entrant in the new and potentially high growth market of probiotic skin health.

It added that since 2010, microbiome companies have attracted around US$840mln in equity investments globally.

The firm’s proprietary probiotic platform, SkinBiotix, has completed three toxicity tests with no safety issues, clearing a hurdle in the regulatory process and further de-risking the pathway to commercialisation.

WATCH: SkinBioTherapeutics 'making very good headway' in development of three key programmes

The company intends to conduct and complete a volunteer study for the cosmetic application of SkinBiotix in 2018, and positive data should permit labelling of the cosmetic as ‘dermatologically tested’.

Northland pointed out that cosmetic studies are shorter than drug trials, providing a shorter path to commercialisation.

The company operates a semi-virtual business structure and focuses on developing commercially-ready technology to be licensed to larger companies for marketing of the end-product.

It has already signed a material transfer agreement with an unnamed global consumer goods company which demonstrates the level of interest from potential partners and the commercial prospects of the SkinBiotix platform.

READ: SkinBioTherapeutics says global consumer goods company is looking at its technology

The broker noted that the microbiome is a growing area and is attracting significant interest from large cosmetic and consumer goods companies, including L’Oréal, Procter & Gamble and Johnson & Johnson.

Dr Cath O’Neill, CEO of SkinBio, in collaboration with Professor Andrew McBain of the University of Manchester, first began investigating the role of the microbiome in skin health.

Their proof-of-principle research focused on the use of probiotics, beneficial bacteria, to improve skin wellbeing, including barrier strength, wound healing and infection control.

In 2016, AIM-listed OptiBiotix Health PL (LON:OPTI) – an healthcare company developing nutraceuticals which modulate the human microbiome - recognised the commercial potential of O’Neill’s research and acquired the technology and associated IP from the University of Manchester.

OptiBiotix subsequently chose to spin-out SkinBio as a separate entity to crystallise the value in the business.

Northland concluded that, in its view, SkinBio’s market capitalisation has not risen to reflect the progress in operations demonstrated by the year’s milestones. Therefore, the broker thinks, the company is significantly undervalued.

]]>
Thu, 19 Apr 2018 14:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195382/skinbiotheraputics-significantly-undervalued-despite-having-demonstrated-significant-progress-195382.html
<![CDATA[Media files - 'Huge milestone' for SkinBioTherapeutics with cream formulation success ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9076/-huge-milestone-for-skinbiotherapeutics-with-cream-formulation-success-9076.html Tue, 17 Apr 2018 12:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9076/-huge-milestone-for-skinbiotherapeutics-with-cream-formulation-success-9076.html <![CDATA[News - SkinBioTherapeutics surges on cream formulation success ]]> https://www.proactiveinvestors.co.uk/companies/news/195124/skinbiotherapeutics-surges-on-cream-formulation-success-195124.html Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) said the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.

The cream formulation will now undergo further testing for stability in the coming weeks.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company's SkinBiotix platform uses extracts of probiotic bacteria for application to the skin and SkinBio has shown in skin models that its technology can improve the skin's barrier function.

The data from the tests showed a direct correlation between the amount of SkinBiotix within the cream and the level present of a specific protein essential to the barrier function of the skin. Work on creating skin lotion and gel formulations is ongoing.

"The incorporation of our SkinBiotix technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year," said Dr Catherine O'Neill, the chief executive officer of SkinBioTherapeutics.

Shares in SkinBio opened 6.4% higher at 10.375p.

]]>
Tue, 17 Apr 2018 08:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195124/skinbiotherapeutics-surges-on-cream-formulation-success-195124.html
<![CDATA[RNS press release - Positive cream formulation results for SkinBiotix ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180417070003_13606608/ Tue, 17 Apr 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180417070003_13606608/ <![CDATA[Media files - Industry heavyweights 'sitting up and taking notice' of SkinBio's technology ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8990/industry-heavyweights-sitting-up-and-taking-notice-of-skinbio-s-technology-8990.html Wed, 04 Apr 2018 08:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/8990/industry-heavyweights-sitting-up-and-taking-notice-of-skinbio-s-technology-8990.html <![CDATA[News - SkinBioTherapeutics says global consumer goods company is looking at its technology ]]> https://www.proactiveinvestors.co.uk/companies/news/194114/skinbiotherapeutics-says-global-consumer-goods-company-is-looking-at-its-technology-194114.html Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) has granted access to its proprietary SkinBiotix technology to a major, global consumer goods company.

Having shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to a material transfer agreement - a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology.

Should the unnamed consumer goods company like what it sees, the arrangement could lead to a commercial arrangement between the two companies.

While at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology, SkinBioTherapeutics is encouraged by the level of interest that has been shown in its pre-clinical data.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company is initially targeting cosmetic skin care and in this market, SkinBioTherapeutics' skin microbiome technology is unusual in that its properties are supported by scientific data, SkinBio said.

The demonstrated properties support potential opportunities for the company in cosmetics, anti-infectives and dermatological indications (e.g. eczema).

"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry," said Dr Cath O’Neill, the chief executive officer of SkinBioTherapeutics. 

Motif’s joint broker, Northland Capital Partners, said: “It is encouraging that SkinBio Therapeutics is progressing to an MTA with a global consumer goods company. This demonstrates the potential commercial promise of the company’s technology.”

Shares in Motif were up 5.9% at 9p in lunchtime trading.

--- adds broker comment and share price reaction ---  

]]>
Tue, 03 Apr 2018 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194114/skinbiotherapeutics-says-global-consumer-goods-company-is-looking-at-its-technology-194114.html
<![CDATA[RNS press release - SBTX signs MTA with global consumer goods company ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180403070007_13588364/ Tue, 03 Apr 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180403070007_13588364/ <![CDATA[Media files - SkinBioTherapeutics 'making very good headway' in development of three key programmes ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8805/skinbiotherapeutics-making-very-good-headway-in-development-of-three-key-programmes-8805.html Mon, 26 Feb 2018 16:02:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/8805/skinbiotherapeutics-making-very-good-headway-in-development-of-three-key-programmes-8805.html <![CDATA[News - SkinBioTherapeutics on track to start first human study for its cosmetic application this year ]]> https://www.proactiveinvestors.co.uk/companies/news/191969/skinbiotherapeutics-on-track-to-start-first-human-study-for-its-cosmetic-application-this-year-191969.html Skin-health specialist SkinBioTherapeutics PLC (LON:SBTX) remains on track with the development of its three flagship programmes.

In its half-year results statement covering the second half of 2017, the life sciences company said it ended the year with £3.6mln in cash, up from £400,000 or so a year earlier.

READ: SkinBioTherapeutics awarded first patent in Australia

Dr Cath O'Neill, the company's chief executive officer, said that since the company's flotation last year, the team had consistently delivered on the objectives outlined in its Aim admission document.

During the reporting period, the priorities were expanded to include the manufacturing and scale-up capability and testing of the initial formulations.

The manufacture of the chemical compound has been successfully replicated and scaled-up by a third party to 50 times the volume currently produced in the laboratory.

The company can now produce sufficient volumes to support the formulation work and the forthcoming cosmetic human study, and the next stage will be to achieve industrial size scale-up, which it is currently working on.

In the meantime, the company is still debating whether to produce the formulation as a gel, a cream or a lotion.

The progress made across all these areas has ensured that the company remains on track to start its first human study for the cosmetic application in the third quarter of this year. The execution and results of this study will be a key point for the development of the cosmetic product, which is already generating early, initial interest from potential commercial partners, O'Neill revealed.

Anti-infection and eczema

Elsewhere, further progress has been made with the anti-infection and eczema programmes.

A 'time-course' study has confirmed that the frequency of application required for protection is three times daily; this indicates that for protection against the Staphylococcus aureus infection, for both the eczema and anti-infection programmes, an application will be required every five hours.

In addition, the company has finalised a dosing level at which the technology can be used safely, for all three programmes.

With this programme progression, the management team has been able to build upon extensive industry relationships and early-stage commercial discussions continue regarding both the cosmetic application and the core SkinBiotix technology, O'Neill revealed.

READ: SkinBioTherapeutics technology gets double green light - next stop human studies

As a pre-revenue company, the profit & loss numbers are not especially relevant, but for the record the loss before tax widened to £386,523 from £254,990 in the second half of 2016, partly reflecting an increase in research & development costs to £125,283 from £89,952 the year before.

"We have made significant progress in the past six months around our SkinBiotix technology and we are on track with the advancement of all three indications in cosmetics, anti-infection and eczema," O'Neill said.

"There is a growing awareness of our SkinBiotix platform technology from the skin healthcare industry, based on the reputation of our team and our 'science-led' business approach. With continued work on our technology and the start of human studies in Q3, we are building further value for shareholders and a strong position from which to hold potential commercial discussions," she added.

Northland Capital Partners was looking forward to SkinBio sealing some licensing opportunities.

"The skin microbiome is becoming an increasingly important field of scientific research. SkinBioTherapeutics has observed that the cosmetic industry is transitioning to products and applications with scientific validation. Having this at its core, the key focus to date has centred on preparation for the initial human studies, which should lead to further commercial negotiations in partnering and licensing opportunities," the broker said.

The shares were down half a penny at 8p in mid-morning trading. 

--- adds broker comment and share price ---

]]>
Wed, 21 Feb 2018 09:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/191969/skinbiotherapeutics-on-track-to-start-first-human-study-for-its-cosmetic-application-this-year-191969.html
<![CDATA[RNS press release - Half year results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180221070003_13540126/ Wed, 21 Feb 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180221070003_13540126/ <![CDATA[RNS press release - Notice of Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180216100254_13536144/ Fri, 16 Feb 2018 10:02:54 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180216100254_13536144/ <![CDATA[RNS press release - Appointment of Joint Broker ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180105070003_13486196/ Fri, 05 Jan 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20180105070003_13486196/ <![CDATA[News - SkinBioTherapeutics awarded first patent in Australia ]]> https://www.proactiveinvestors.co.uk/companies/news/188119/skinbiotherapeutics-awarded-first-patent-in-australia-188119.html SkinBioTherapeutics PLC (LON:SBTX) has been granted a first patent in Australia for Skinbiotix, its probiotic skin health platform.

The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease and runs until 15 March 2033, the company said in a statement on Friday.

READ: SkinBioTherapeutics technology gets double green light - next stop human studies

Catherine O'Neill, SkinBioTherapeutics’ chief executive, said: "The Australian skincare market is a key global market.

“The progression and successful grant of the first national patent to emerge from the company's Skinbiotix patent family underpins the commercial potential worldwide.

"This is a step forward in preparing for human trials, which are scheduled for 2018."

]]>
Fri, 01 Dec 2017 10:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/188119/skinbiotherapeutics-awarded-first-patent-in-australia-188119.html
<![CDATA[RNS press release - Notification of first patent grant ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171201070543_13450377/ Fri, 01 Dec 2017 07:05:43 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171201070543_13450377/ <![CDATA[News - SkinBioTherapeutics technology gets double green light - next stop human studies ]]> https://www.proactiveinvestors.co.uk/companies/news/186987/skinbiotherapeutics-technology-gets-double-green-light-next-stop-human-studies-186987.html SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology has passed two additional and final toxicity tests, meaning it is safe to use in the company’s three target markets.

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells).

Prior to that, SkinBiotix was found not to be cytotoxic, which in layman’s terms meant it didn’t kill cells it came in contact with.

Focusing on efficacy

"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focusing on further proving its efficacy,” said Dr Catherine O'Neill, chief executive of SkinBioTherapeutics.

The company is focused on developing products and treatments that effect the portion of the human microbiome that resides on the skin.

This is a mix of bacteria, yeasts, and parasites that live on the body’s biggest organ.  Sounds gross, but this microbial ecosystem is thought to be key to skin health.

READ: SkinBiotherapeutics readying for cosmetic cream launch after safety test success

Based on the work of CEO O’Neill at Manchester University, the SkinBiotix platform is protected by three patent families and 18 patent applications.

It is also supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

As mentioned above, the firm is developing three products that manage, protect and restore the body’s outer layer.

First cab off the rank

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

WATCH: SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’ commercialisation talks.

Tentative discussions have already begun, said CEO O’Neill, but human data is crucial to the process. 

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

In the release Thursday, the company said it was confident of human studies getting underway next year.

]]>
Thu, 09 Nov 2017 07:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/186987/skinbiotherapeutics-technology-gets-double-green-light-next-stop-human-studies-186987.html
<![CDATA[RNS press release - SkinBiotix platform passes external toxicity tests ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171109070004_13425405/ Thu, 09 Nov 2017 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171109070004_13425405/ <![CDATA[RNS press release - SkinBioTherapeutics to present at investor evening ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171108113250_13424746/ Wed, 08 Nov 2017 11:32:50 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171108113250_13424746/ <![CDATA[News - SkinBiotherapeutics readying for cosmetic cream launch after safety test success ]]> https://www.proactiveinvestors.co.uk/companies/news/186818/skinbiotherapeutics-readying-for-cosmetic-cream-launch-after-safety-test-success-186818.html SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’ commercialisation talks.

Tentative discussions have already begun, Cath O’Neill, the skin microbiome specialist’s chief executive told Proactive Investors, but human data is crucial to the process.  

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

WATCH:SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

Work on the formulation of the skin cream has also started, O’Neill said, adding this was another crucial part of the product development process.

SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin.

SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added.

“Once the results [from the human study] are in we are good to go.”

SkinBiotix might be either an ingredient in someone else’s product or a brand in its own right.

O’Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report.

She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category.

“SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.”

The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment.

Shares rose 1% to 10.3p.

]]>
Mon, 06 Nov 2017 14:45:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/186818/skinbiotherapeutics-readying-for-cosmetic-cream-launch-after-safety-test-success-186818.html
<![CDATA[Media files - SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8319/skinbiotherapeutics-dr-cath-o-neill-named-one-of-healthcare-s-top-movers-and-shakers-8319.html Thu, 02 Nov 2017 10:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/8319/skinbiotherapeutics-dr-cath-o-neill-named-one-of-healthcare-s-top-movers-and-shakers-8319.html <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171030112303_13413220/ Mon, 30 Oct 2017 11:23:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171030112303_13413220/ <![CDATA[News - Antibiotic concerns highlight Skinbiotherapeutics' infections potential ]]> https://www.proactiveinvestors.co.uk/companies/news/185884/antibiotic-concerns-highlight-skinbiotherapeutics-infections-potential-185884.html A very scary picture of a world where antibiotics don’t work anymore was delivered in October by the UK’s chief medical officer.

“The world is facing an antibiotics apocalypse, said Dame Sally Davies, who predicted around 700,000 people a year would die from drug-resistant infections unless major medical advances were made.

SkinBiotherapetics PLC (LON:SBTX) chief executive Cath O’Neil published a study on the potential of skin probiotics as an anti-bacterial when she was working as a senior lecturer at the division of Musculoskeletal and Dermatological Science at the University of Manchester .

In the research, the team from Manchester showed specific types of bacteria could protect skin cells in the laboratory from infection by S. aureus, an infection carried in the noses of 30% of people.

While the skin normally provides a major barrier, during surgery for example it can enter the body with devastating consequences.

Tests against bacterial strains

Skinbiotherpeutics is carrying on this work and now testing to see if its flagship product, Skinbiotix, can prevent the attachment of S.aureus, the most common of skin pathogens, to skin cells.

S.aureus is the casue of a range of infections from relatively mild diseases such as impetigo to septicemia.

Infections can be treated successfully with antibiotics, but resistant strains, such as Methicillin-Resistant Staphylococcus Aureus ("MRSA"), are emerging, Skinbiotherapeutics said.

Tests are for SkinBiotix's inhibitory activity in skin cells against a panel of bacterial strains known to be of importance in Healthcare Acquired Infections (HCAIs).

 Albeit at an early stage compared to the cosmetic programme, good progress has been made, the company said recently.

  ]]>
Thu, 19 Oct 2017 12:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185884/antibiotic-concerns-highlight-skinbiotherapeutics-infections-potential-185884.html
<![CDATA[News - SkinBioTherapeutics results chart a year of significant progress ]]> https://www.proactiveinvestors.co.uk/companies/news/185096/skinbiotherapeutics-results-chart-a-year-of-significant-progress-185096.html Annual results from SkinBioTherapeutics PLC (LON:SBTX) chart a period of significant progress, including April’s listing on AIM (which brought in £4.5mln) and the demonstration of the three modes of action of its platform, SkinBiotix.

It is developing the technology as a cosmetic, a hand cream that protects against hospital-acquired infections and a treatment for eczema.

WATCH: SkinBioTherapeutics sees flagship technology take critical next step

The SkinBiotix platform has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

The intellectual property was spun out of the University of Manchester and specifically the work of Dr Catherine O’Neill, who is now the company’s chief executive.

Made in Manchester 

SkinBio has a research agreement with the university to develop a bacterial lysate. The company is currently scaling up manufacture from the small batches it produces, it said Thursday.

The financial results for the year to June 30 showed the newly-listed business was sitting on £3.9mln as at that date. It posted a loss of £673,000, which is modest for a company in the R&D phase.

"During the year, we have demonstrated three significant properties - barrier improvement, anti-infection and repair - which form the foundations of our three development programmes. We are making good scientific headway and are starting initial discussions with partners,” said CEO O’Neill.

"Operationally, we have made a good start to the new financial year, especially with the recent news around the third party cytotoxicity testing, and we look forward to reporting on the next phase of the company's journey."

READ: SkinBioTherapeutics PLC technology passes crucial milestone after independent test

On Tuesday, the firm said its flagship technology had passed a key safety test as it updated on progress.

Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

Three products

As mentioned above, it is developing three products that manage, protect and restore the body’s largest organ.

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

]]>
Thu, 05 Oct 2017 07:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185096/skinbiotherapeutics-results-chart-a-year-of-significant-progress-185096.html
<![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171005070003_13386538/ Thu, 05 Oct 2017 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171005070003_13386538/ <![CDATA[Media files - SkinBioTherapeutics sees flagship technology take critical next step ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/8183/skinbiotherapeutics-sees-flagship-technology-take-critical-next-step-8183.html Tue, 03 Oct 2017 15:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/8183/skinbiotherapeutics-sees-flagship-technology-take-critical-next-step-8183.html <![CDATA[News - SkinBioTherapeutics PLC technology passes crucial milestone after independent test ]]> https://www.proactiveinvestors.co.uk/companies/news/184960/skinbiotherapeutics-plc-technology-passes-crucial-milestone-after-independent-test-184960.html SkinBioTherapeutics PLC (LON:SBTX) said its flagship technology had passed a key safety test as it updated on progress.

Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

READ: SkinBioTherapeutics - New listing in the emerging field of the human microbiome has multiple value trigger points

SkinBio said no cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration.

The data backed up in-house results compiled by the company, which listed on the stock market in April.

“This was one of the key milestones to pass and was highlighted as such at the IPO,” said chief executive, Dr Catherine O’Neill.

“Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.”

Patents

The SkinBiotix platform is protected by three patent families and 18 patent applications and is supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

From that it is developing three products that manage, protect and restore the body’s largest organ.

READ: SkinBioTherapeutics 'starting early conversations with potential commercial partners'

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Three phases

Pilot formulation has begun with an outside partner with expertise in cosmetics. Phase one of three is complete: testing the solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway.

At the same time, a study has determined the cream is best applied every five hours for protection against infection.

In the update, SkinBioTherapeutics said it had finalised a dosing level at which the technology will be used which maintains the viability of the skin cells.

It has also received confirmation of the modifying property of SkinBiotix on the protein composition of the skin, increasing the expression of a protein called Claudin 4 that help protect the skin.

Early-stage commercial discussions have also begun with both would-be licensees and manufacturers.

"Operationally, we are on track,” said CEO O’Neill. “The development programmes are progressing well, we are generating further scientific data on SkinBiotix confirming its suitability for application to skin, and industry awareness of our technology is growing."

]]>
Tue, 03 Oct 2017 07:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184960/skinbiotherapeutics-plc-technology-passes-crucial-milestone-after-independent-test-184960.html
<![CDATA[RNS press release - Cytotoxicity results and scientific update ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171003070003_13383393/ Tue, 03 Oct 2017 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20171003070003_13383393/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20170927090001_13376966/ Wed, 27 Sep 2017 09:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20170927090001_13376966/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20170912085400_13359555/ Tue, 12 Sep 2017 08:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15708/LSE20170912085400_13359555/